| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1151: Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal) |
|
Medicine details |
|
| Medicine name | inebilizumab (Uplizna®) |
| Formulation | 100 mg concentrate for solution for infusion |
| Reference number | 9420 |
| Indication | Treatment for immunoglobulin G4-related disease |
| Company | Amgen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 06/05/2026 |
| NICE guidance | TA1151: Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal) |